XPO1 and colorectal carcinoma: Our findings demonstrate that suppressing nuclear export of BATF2 via mutating its NES region or inhibiting CRM1 expression may serve as a promising therapeutic strategy against CRC proliferation, which may shed new light on the exploration of novel combined therapeutic strategies for CRC patients.